PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer Read more
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership Read more
Syncromune Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax Immunotherapy Platform Read more
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Read more
ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia Read more
Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron Read more